KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Net Margin (2016 - 2025)

Biogen has reported Net Margin over the past 17 years, most recently at 2.15% for Q4 2025.

  • Quarterly results put Net Margin at 2.15% for Q4 2025, down 1301.0% from a year ago — trailing twelve months through Dec 2025 was 13.07% (down 380.0% YoY), and the annual figure for FY2025 was 13.07%, down 380.0%.
  • Net Margin for Q4 2025 was 2.15% at Biogen, down from 18.4% in the prior quarter.
  • Over the last five years, Net Margin for BIIB hit a ceiling of 45.59% in Q3 2022 and a floor of 4.85% in Q3 2021.
  • Median Net Margin over the past 5 years was 16.26% (2021), compared with a mean of 15.56%.
  • Biggest five-year swings in Net Margin: skyrocketed 5044bps in 2022 and later tumbled -4813bps in 2023.
  • Biogen's Net Margin stood at 3.72% in 2021, then skyrocketed by 691bps to 21.97% in 2022, then plummeted by -53bps to 10.43% in 2023, then rose by 4bps to 10.86% in 2024, then plummeted by -120bps to 2.15% in 2025.
  • The last three reported values for Net Margin were 2.15% (Q4 2025), 18.4% (Q3 2025), and 24.0% (Q2 2025) per Business Quant data.